Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review223
Systemic therapy for older patients with early breast cancer216
Editorial Board203
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)196
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty141
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer128
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis119
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives116
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis107
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer104
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas99
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in88
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials84
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group76
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer75
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?74
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis74
Editorial Board73
Emerging antibody-based therapies for the treatment of acute myeloid leukemia69
Optimizing care in early phase cancer trials: The role of palliative care66
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis65
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches64
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features62
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.61
If it’s a target, it’s a pan-cancer target: Tissue is not the issue58
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC57
Uncertainties and controversies in axillary management of patients with breast cancer57
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges56
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials55
Editorial Board54
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment52
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck51
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes50
Roadmap to cure multiple myeloma49
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations48
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?47
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design44
The immunogram of inflammatory breast cancer44
Editorial Board44
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review44
Overview of BH3 mimetics in ovarian cancer43
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier43
Extracellular vesicles and the “six Rs” in radiotherapy42
0.039944171905518